Quantification of gliclazide by semi-micro high-performance liquid chromatography

Application to a bioequivalence study of two formulations in healthy subjects

Ji-Young Park, Kyoung Ah Kim, Su Lyun Kim, Pil Whan Park

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The objective of the present study was to evaluate the bioequivalence of two formulations of gliclazide in healthy human volunteers. Bioequivalence of the two formulations was determined in 20 healthy subjects with a single-dose, two-period, crossover study. A new high-performance liquid chromatographic method for the pharmacokinetic analysis of gliclazide was developed, using a semi-micro column to quantify gliclazide in plasma samples. Chromatographic separation was achieved with a semi-micro C18 column and 40 mM KH2PO4 (pH 4.6)-acetonitrile-isopropyl alcohol (5:4:1, v/v/v) as the mobile phase, and with UV detection at 229 nm. The method displayed good precision (coefficients of variation (CV<8.0%)), was fast (total analysis time 8 min), and required only a small amount of mobile phase (0.22 ml/min), with a reasonable limit of quantification (0.1 μg/ml). The calibration curve was linear in the concentration range 0.1-10 μg/ml. When the pharmacokinetic parameters of gliclazide in the two formulations were calculated and compared statistically using crossover analysis of variance, they were similar, with no statistically significant difference. Ninety percent confidence intervals for AUC0-last, AUC0-∞, and Cmax, used to evaluate bioequivalence, were in the stipulated range of 0.80-1.25. This result suggests that two formulations are bioequivalent when administered orally at a dose of 80 mg gliclazide.

Original languageEnglish
Pages (from-to)943-949
Number of pages7
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume35
Issue number4
DOIs
Publication statusPublished - 2004 Jun 29
Externally publishedYes

Fingerprint

Gliclazide
Therapeutic Equivalency
High performance liquid chromatography
Healthy Volunteers
High Pressure Liquid Chromatography
Pharmacokinetics
2-Propanol
Analysis of variance (ANOVA)
Cross-Over Studies
Calibration
Analysis of Variance
Confidence Intervals
Plasmas
Liquids

Keywords

  • Bioequivalence
  • Gliclazide
  • Semi-micro column

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

@article{fb986a46c899412389e310fb43d1bbcf,
title = "Quantification of gliclazide by semi-micro high-performance liquid chromatography: Application to a bioequivalence study of two formulations in healthy subjects",
abstract = "The objective of the present study was to evaluate the bioequivalence of two formulations of gliclazide in healthy human volunteers. Bioequivalence of the two formulations was determined in 20 healthy subjects with a single-dose, two-period, crossover study. A new high-performance liquid chromatographic method for the pharmacokinetic analysis of gliclazide was developed, using a semi-micro column to quantify gliclazide in plasma samples. Chromatographic separation was achieved with a semi-micro C18 column and 40 mM KH2PO4 (pH 4.6)-acetonitrile-isopropyl alcohol (5:4:1, v/v/v) as the mobile phase, and with UV detection at 229 nm. The method displayed good precision (coefficients of variation (CV<8.0{\%})), was fast (total analysis time 8 min), and required only a small amount of mobile phase (0.22 ml/min), with a reasonable limit of quantification (0.1 μg/ml). The calibration curve was linear in the concentration range 0.1-10 μg/ml. When the pharmacokinetic parameters of gliclazide in the two formulations were calculated and compared statistically using crossover analysis of variance, they were similar, with no statistically significant difference. Ninety percent confidence intervals for AUC0-last, AUC0-∞, and Cmax, used to evaluate bioequivalence, were in the stipulated range of 0.80-1.25. This result suggests that two formulations are bioequivalent when administered orally at a dose of 80 mg gliclazide.",
keywords = "Bioequivalence, Gliclazide, Semi-micro column",
author = "Ji-Young Park and Kim, {Kyoung Ah} and Kim, {Su Lyun} and Park, {Pil Whan}",
year = "2004",
month = "6",
day = "29",
doi = "10.1016/j.jpba.2004.02.025",
language = "English",
volume = "35",
pages = "943--949",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Quantification of gliclazide by semi-micro high-performance liquid chromatography

T2 - Application to a bioequivalence study of two formulations in healthy subjects

AU - Park, Ji-Young

AU - Kim, Kyoung Ah

AU - Kim, Su Lyun

AU - Park, Pil Whan

PY - 2004/6/29

Y1 - 2004/6/29

N2 - The objective of the present study was to evaluate the bioequivalence of two formulations of gliclazide in healthy human volunteers. Bioequivalence of the two formulations was determined in 20 healthy subjects with a single-dose, two-period, crossover study. A new high-performance liquid chromatographic method for the pharmacokinetic analysis of gliclazide was developed, using a semi-micro column to quantify gliclazide in plasma samples. Chromatographic separation was achieved with a semi-micro C18 column and 40 mM KH2PO4 (pH 4.6)-acetonitrile-isopropyl alcohol (5:4:1, v/v/v) as the mobile phase, and with UV detection at 229 nm. The method displayed good precision (coefficients of variation (CV<8.0%)), was fast (total analysis time 8 min), and required only a small amount of mobile phase (0.22 ml/min), with a reasonable limit of quantification (0.1 μg/ml). The calibration curve was linear in the concentration range 0.1-10 μg/ml. When the pharmacokinetic parameters of gliclazide in the two formulations were calculated and compared statistically using crossover analysis of variance, they were similar, with no statistically significant difference. Ninety percent confidence intervals for AUC0-last, AUC0-∞, and Cmax, used to evaluate bioequivalence, were in the stipulated range of 0.80-1.25. This result suggests that two formulations are bioequivalent when administered orally at a dose of 80 mg gliclazide.

AB - The objective of the present study was to evaluate the bioequivalence of two formulations of gliclazide in healthy human volunteers. Bioequivalence of the two formulations was determined in 20 healthy subjects with a single-dose, two-period, crossover study. A new high-performance liquid chromatographic method for the pharmacokinetic analysis of gliclazide was developed, using a semi-micro column to quantify gliclazide in plasma samples. Chromatographic separation was achieved with a semi-micro C18 column and 40 mM KH2PO4 (pH 4.6)-acetonitrile-isopropyl alcohol (5:4:1, v/v/v) as the mobile phase, and with UV detection at 229 nm. The method displayed good precision (coefficients of variation (CV<8.0%)), was fast (total analysis time 8 min), and required only a small amount of mobile phase (0.22 ml/min), with a reasonable limit of quantification (0.1 μg/ml). The calibration curve was linear in the concentration range 0.1-10 μg/ml. When the pharmacokinetic parameters of gliclazide in the two formulations were calculated and compared statistically using crossover analysis of variance, they were similar, with no statistically significant difference. Ninety percent confidence intervals for AUC0-last, AUC0-∞, and Cmax, used to evaluate bioequivalence, were in the stipulated range of 0.80-1.25. This result suggests that two formulations are bioequivalent when administered orally at a dose of 80 mg gliclazide.

KW - Bioequivalence

KW - Gliclazide

KW - Semi-micro column

UR - http://www.scopus.com/inward/record.url?scp=2942612501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942612501&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2004.02.025

DO - 10.1016/j.jpba.2004.02.025

M3 - Article

VL - 35

SP - 943

EP - 949

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 4

ER -